The 2021 National Breast Cancer Conference and CSCO Breast Cancer Annual Conference held multiple guidelines...

On April 9-10, 2021, the 2021 National Breast Cancer Conference and the Chinese Society of Clinical Oncology (CSCO) Breast Cancer Annual Meeting will be held in Beijing.

The conference specially set up various special sessions such as "Science Frontier Progress, Real World Research, Innovative Drug Research and Development, Famous Perspective, BestofBCC, CSCO BC Guide Release, Clinical Practice and Artificial Intelligence", and added "Youth Salon, Breast Cancer Cases" Management Forum, CSCO BC Guide Update and Artificial Intelligence Doctor Seminar” and other sub-forums.

1.

The "CSCO Guidelines for Breast Cancer Diagnosis and Treatment" has always taken into account the differences in regional development, the accessibility of diagnosis and treatment methods and the social value of tumor treatment, and is committed to recommending the best treatment plan for China and similar countries and regions.

1) Keeping up with the cutting-edge academic progress, precision pathological diagnosis and treatment

In this guideline update, the primary update highlight is the addition of multiple content in pathological diagnosis, so as to provide more basis for clinical diagnosis and treatment.

2) In-depth analysis of disease types and therapeutic drugs to meet the needs of clinical practice

Triple-negative breast cancer is a type of breast cancer with strong heterogeneity.

With the deepening of research and exploration of CDK4/6 inhibitor drugs, clinical studies have determined the status and role of CDK4/6 inhibitors combined with endocrine therapy in hormone receptor-positive advanced breast cancer patients, but different types of CDK 4/6 inhibitors The mechanism of action, usage and dosage, indications, and adverse reactions are not completely consistent.

3) Develop real-world research and complement and promote evidence-based research

Real-world data refers to data from various sources related to the health of patients and/or collected during daily medical procedures.

2.

In recent years, new anti-HER2 drugs such as Pertuzumab, lapatinib, pyrrotinib and T-DM1 have been successfully developed and marketed, and have achieved good results in the treatment of HER2-positive breast cancer, which has changed clinical practice.

3.

The incidence of bone metastasis in advanced breast cancer can be as high as 65% to 75%, and bone metastasis accounts for 27% to 50%.

2.

3.

In order to promote the exchanges and learning of young scholars and establish friendship, the 2021 National Breast Cancer Conference on April 8th will specially set up a special youth salon to express hope and encouragement for young scholars to work hard.
In this youth salon, young talents in the field of breast cancer in my country shared reports on "How young scholars conduct clinical research" and "Statistical methods and design of real-world research".
In addition, many young doctors from all over the country shared the latest articles published by their teams, sharing their experiences from multiple perspectives such as selecting questions, data collection and analysis, article writing and publication.

4.
Guidelines update and artificial intelligence doctor seminar held, combined with actual cases to demonstrate the clinical application of AI

In order to train more qualified guideline interpreters and smart doctors, during the 2021 National Breast Cancer Conference, special guideline updates and artificial intelligence seminars were set up with experts from 15 provinces and cities including Beijing, Hebei, Shanghai, Jiangxi, and Sichuan.
Participated in this seminar.
During the conference, the speaker demonstrated the operating system and functions of the CSCO AI intelligent system with the help of cases of HR-positive advanced breast cancer.
Many doctors from all over the country carried out the operation and demonstration of the intelligent system in combination with actual cases.
Other experts at the meeting commented on its interpretation and presentation.
At present, the CSCO AI intelligent decision-making system has formed an important function of intelligent decision-making, evidence support, adverse reactions, cost reference, and patient follow-up.
And to carry out the training of smart doctors in many places across the country.
CSCO AI has carried out nearly 10,000 applications to help reduce the direct diagnosis and treatment costs of patients and improve survival prognosis.

5.
Prepare the breast cancer case management forum and implement the concept of individualized tumor management throughout the process

Based on the standardization of tumor treatment, individualized treatment is also an important part of clinical diagnosis and treatment due to differences in tumor staging, pathological types and even individual differences in patients.
In order to better promote the concept of individualized management of breast cancer, a special case management nursing session was set up in this National Breast Cancer Conference.
It is believed that the tacit cooperation between nursing and clinical practice can further standardize and promote the breast cancer case management model.
So as to provide individualized and comprehensive clinical management mode for the clinical treatment of breast cancer patients in my country, and benefit the patients.

With the grand promulgation of the latest version of the CSCO BC guideline and the CSCO AI artificial intelligence system, the "2021 CSCO Breast Cancer Diagnosis and Treatment Guide" tour will also be officially launched, and the implementation of the CSCO AI intelligent system is also in full swing.
The conference hopes that through a series of activities such as follow-up guide interpretation and case discussion, with the help of CSCO BC guidelines and artificial intelligence system, China’s standardized diagnosis and treatment of breast cancer will be further enhanced and popularized, so that more doctors and patients across the country will gain access.
beneficial.